curative D2 lymphadenectomy. 7, 8 However, despite undergoing adjuvant treatment for 6 months to 1 year after surgery, approximately one-fourth of patients in the chemotherapy group demonstrated recurrence in both studies. 7, 8 In order to examine a potential improvement in survival for gastric cancer patients, it is necessary to identify a subgroup of patients who are expected to show a poor response to adjuvant treatments.
S-1 (previously known as TS-1) is an oral formulation of 5-fluorouracil (5-FU) consisting of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur), 5-chloro-2,4-dihydroxypyridine, and potassium oxonate (Oxo) in a molar ratio of 1.0:0.4:1.0. 9 The aim of the Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)
was to evaluate the efficacy of TS-1 in relation to long-term survival compared with surgery alone in stage II or III gastric cancer. 8 The aim of the CLASSIC study was to evaluate the effect on longterm survival of adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy. Given that neither partial nor total gastrectomy was found to affect the pharmacokinetics of 5-FU derived from S-1, its use appears to be suitable in the postoperative adjuvant setting for advanced stage gastric cancer patients. Despite that fact, in the ACTS-GC study, 34.2% of patients treated with S-1 withdrew from treatment and 27.8% showed recurrence after treatment with S-1. 8 To date, several reports have described how to modify the schedule of adjuvant S-1 in order to maintain a full year of treatment, as well as to predict patient compliance with S-1 treatment. [10] [11] [12] Aoyama et al. 13 reported that the level of creatinine clearance was a significant risk factor for the continued use of S-1 adjuvant treatment. To our knowledge, there is no previous report that clarifies whether the continued use of S-1 has an effect on patient prognosis. Moreover, there are a few reports that describe the safety and feasibility of adjuvant S-1 chemotherapy in a Korean population. 14 (Table 1 ).
The median time until the initiation of the adjuvant chemotherapy after surgery was 31.9 days (range: 16~52 days).
Results of S-1 administration
Data regarding adverse events on the 49 patients who received adjuvant S-1 were prospectively collected for analysis. Adverse events of grade 1, 2, 3, or 4 were defined according to the NCI-CTCAE, including, gastrointestinal, hematologic, neurologic, and dermatologic symptoms. 15 Grade 3 and 4 toxicities occurred in 1.9% and 5.7% of patients, respectively. Common side effects are outlined in Table 2 and included grade 3 and 4 diarrhea, oral ulcers, and skin rash.
Twenty-nine patients completed S-1 dosing and 20 patients discontinued S-1 treatment. Twenty patients (40.8%) completed the 1-year schedule with full-dose administration and 9 patients required dose reduction. The causes of incomplete S-1 dosing are outlined in Table 3 and include disease progression (n=7), side effects (n=9), and others (n=4).
Oncologic outcomes of patients
During the follow-up period, recurrent disease was diagnosed in 12 patients (24.5%). The most common types of recurrence were spread to distant lymph nodes and hematogenous spread to the liver. Ultimately, 7 patients died due to cancer recurrence (Table 4) .
We analyzed the correlation between various clinicopathologic factors and oncologic outcomes. In the univariate analysis, stage III disease and non-completion of S-1 treatment were significantly correlated with worse disease-free survival and overall survival rates, and the differentiation of the primary tumor was related to the overall survival rate ( (Table 7) .
Additionally, we analyzed the disease-free or overall survival rates of 42 patients after the exclusion of 7 patients who received incomplete S-1 treatment due to recurrence, in order to remove bias. Of the 42 patients, 13 patients with non-completion of S-1 still demonstrated a worsening of the disease-free survival rate when compared to patients with completion of S-1 treatment (Fig. 1 ).
Discussion
Our study demonstrates that 1 year of adjuvant S-1 treatment after gastric cancer surgery in a Korean patient population with stage II and III gastric cancer disease is well tolerated. In addition, our study emphasizes that non-continuation of adjuvant S-1 treatment during the 1-year period after surgery is significantly associated with a high risk of recurrence and poor survival of patients In particular, as S-1 was developed as an orally available 5-FU agent combined with other ingredients to reduce various toxicities, 17 surgeons also have the ability to prescribe it without consultation with an oncologist. In our study, only surgeons performed followup on all enrolled patients and managed the side effects from S-1 administration. Our results showed that the percentage of patients who did not complete a full schedule of S-1 treatment was 40.8%.
Although this figure was 5.7% higher than the results reported by oncologists in another Korean retrospective study, 14 the difference was not statistically significant (data not shown, chi-square test, P=0.428). Of the patients enrolled in the current study, 7 ceased S-1 treatment due to cancer progression. Another 13 patients terminated S-1 treatment due to side effects (n=9) or patient refusal (n=4).
In our study, 28 patients experienced one or more toxicities during their treatment, but most were properly managed, and the number of patients who stopped the medication due to toxicities could be minimized. However, our results suggested that non-completion of S-1 treatment could be an important factor to predict recurrence after surgery.
In our study, the most common side effect that resulted in a dose reduction was diarrhea (5.7%). In the ACTS-GC study, diarrhea was also one of the common side effects (grade 3 or greater, 3.1%). 8 Chemotherapy-induced diarrhea also occurs in 50% to 80% of patients who are administered a chemotherapy regimen. diarrhea until symptoms resolve. However, patients with severe and complicated diarrhea (e.g., fever, sepsis, neutropenia, and bleeding) should be admitted to the hospital and treated with intravenous fluids, antibiotics, and octreotide.
Our study, along with the subgroup analysis of ACTS-GC, shows an unfavorable oncologic outcome in gastric cancer patients with stage III or worse disease in spite of adjuvant S-1 treatment after surgery. 16 The long-term results of the ACTS-GC study demonstrate that adjuvant S-1 monotherapy significantly improves overall survival and the relapse-free survival rate in stage II and IIIA disease. However, in patients with stage IIIB disease, the 5-year overall survival rate was 50.2% in the patients treated with adjuvant S-1 compared to a rate of 44.1% in the surgery only group. The narrow difference between the two groups suggests that future studies should investigate the effectiveness of neoadjuvant or adjuvant treatments with multiple regimens in patients at high risk for recurrence. The previously mentioned CLASSIC trial also showed the effectiveness of oxaliplatin and capecitabine on the overall and relapse-free survival. 7 The authors state that these combined regimens also showed a favorable superiority even in patients and other studies have shown the tolerability of these regimens in patients who have undergone gastrectomy. 26 Further studies would be needed to examine whether S-1 plus cisplatin is superior to S-1 alone.
In conclusion, our results showed that completion of S-1 treatment for 1 year after surgery was the most important factor to predict the outcome of patients with advanced gastric cancer. Even when we excluded the patients who terminated S-1 treatment due to tumor recurrence from the analysis, completion of S-1 treatment was significantly related to a good outcome. Therefore, efforts are needed to control toxicities during S-1 administration, and patients should attempt to complete administration for 1 year if possible. In addition, patients with stage III disease still demonstrate poor outcomes. As a result, it is important to consider other novel regimens for patients at high risk.
